2Burger RA.Overview of anti-angiogenic agents in development for ovarian cancer. Gynecologic Oncology . 2011
3Siddiqui GK,Elmasry K,Wong Te Fong AC,et al.Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer. European Journal of Gynaecological Oncology . 2010
4Matulonis UA.Bevacizumab and its use in epithelial ovarian cancer. Future Oncol . 2011
5Hurt JD,Richardson DL,Seamon LG,et al.Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecologic Oncology . 2009
6Gordon CR,Rojavin Y,Patel M,et al.A review on bevacizumab and surgical wound healing:an important warning to all surgeons. Annals of Plastic Surgery . 2009
7Hirte H,Oza A,Swenerton K,et al.A phase II study of erlotinib(OSI-774)given in combination with carboplatin in patients with recurrent epithelial ovarian cancer(NCIC CTG IND.149). Gynecologic Oncology . 2010
8Kurman RJ,Shih I.The origin and pathogenesis of epithelial ovarian cancer:a proposed unifying theory. The American Journal of Surgical Pathology . 2010
9Coleman RL,Broaddus RR,Bodurka DC,et al.Phase II trial of imatinib mesylate in patients with recurrent platinum-and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecologic Oncology . 2006
10Shah GD,Loizos N,Youssoufian H,et al.Rationale for the development of IMC-3G3,a fully human immunoglobulin G subclass1monoclonal antibody targeting the platelet-derived growth factor receptor alpha. Cancer . 2010
